Filed under: Stocks to Buy

Readers of this space know that the investment bias is toward large-cap companies with demonstrated business models and who have a competitive advantage in established markets, preferably with a favorable global trend as a support. But every once in while an exception is made for a smaller, innovative company, and along this line Masimo looks attractive.

Masimo Corporation (Nasdaq: MASI)’s signal extraction technology non-invasively monitors patients’ arterial blood-oxygen saturation levels and pulse rates.

Analysts like MASI’s product variation, which features pulse oximeters in both hand-held and stand-alone versions, and the company’s client diversity: MASI has sold products to more than 35 medical equipment companies. The Reuters FY 2007/FY 2008 EPS consensus estimates for MASI are $0.66 to $0.50.

Continue reading Masimo believes a smart age requires smart medical tests

Permalink | Email this | Comments

Share This

This entry was posted on Wednesday, January 9th, 2008 at 12:18 am and is filed under Stocks Money News. You can follow any responses to this entry through the RSS 2.0 feed. You can leave a response, or trackback from your own site.